Strategies for Managing Patients With Melanoma
Source: Targeted Oncology, June 2023
Marc S. Ernstoff, MD, chief for the ImmunoOncology branch of the Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis at the National Cancer Institute, provides recommendations for managing patients with metastatic melanoma.
According to Ernstoff, immune checkpoint inhibitors have shown to be durable and provide long-term disease control for patients with melanoma over the last 15 years.
Some of the key advances and developments in this space include agents targeting PD1 like nivolumab (Opdivo) and pembrolizumab (Keytruda), the anti-CTLA4 antibody ipilimumab (Yervoy), the anti-LAG3 antibody relatlimab combined with nivolumab (Opdualag), and more.